{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T19:18:52Z","timestamp":1765135132891,"version":"3.46.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijtb.2024.04.011","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T11:59:29Z","timestamp":1713441569000},"page":"S39-S42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S2","title":["Effectiveness of FDA vital staining in follow UP of DR PTB patients on longer treatment regimen under NTEP"],"prefix":"10.1016","volume":"72","author":[{"given":"Aswathy","family":"S A","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj K.","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2022","series-title":"TB Annual Report India 2022","key":"10.1016\/j.ijtb.2024.04.011_bib1"},{"year":"2019","series-title":"Guidelines for PMDT in India","key":"10.1016\/j.ijtb.2024.04.011_bib2"},{"year":"2005","series-title":"Registration and Reporting","key":"10.1016\/j.ijtb.2024.04.011_bib4"},{"key":"10.1016\/j.ijtb.2024.04.011_bib5","unstructured":"RNTCP, Training Manual for Mycobacterium tuberculosis Culture and Drug Susceptibility Testing.."},{"issue":"1","key":"10.1016\/j.ijtb.2024.04.011_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2307\/3544373","article-title":"Fluorescein diacetate as a stain of metabolically active bacteria in soil","volume":"36","author":"Lundgren","year":"1981","journal-title":"Oikos"},{"issue":"8","key":"10.1016\/j.ijtb.2024.04.011_bib7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/cid\/ciu1153","article-title":"Clinical evaluation of tuberculosis viability microscopy for assessing treatment response","volume":"60","author":"Datta","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ijtb.2024.04.011_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijmyco.2016.06.003","article-title":"Fluorescein diacetate vital staining for detecting viability of acid-fast bacilli in patients on antituberculosis treatment","volume":"5","author":"Kanade","year":"2016","journal-title":"International Journal of Mycobacteriology"},{"issue":"2","key":"10.1016\/j.ijtb.2024.04.011_bib9","first-page":"183","article-title":"A fluorescent staining procedure for determining the viability of Mycobacterial cells","volume":"50","author":"Kvach","year":"1982","journal-title":"Int J Lepr"},{"year":"2011","series-title":"Fluorescent Light-Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis: Policy Statement","key":"10.1016\/j.ijtb.2024.04.011_bib10"},{"key":"10.1016\/j.ijtb.2024.04.011_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3329\/bjms.v11i4.12605","article-title":"Use of fluorescein diacetate (FDA) staining to detect viable Mycobacterium tuberculosis","volume":"11","author":"Islam","year":"2012","journal-title":"Bangladesh J Med Sci"},{"key":"10.1016\/j.ijtb.2024.04.011_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74432-y","article-title":"Prevalence and factors associated with multidrug-resistant tuberculosis in South India","volume":"10","author":"Shivekar","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijtb.2024.04.011_bib13","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.5588\/ijtld.11.0166","article-title":"Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis","volume":"16","author":"Deun","year":"2012","journal-title":"Int J Tubercul Lung Dis : the official journal of the International Union against Tuberculosis and Lung Disease"},{"key":"10.1016\/j.ijtb.2024.04.011_bib14","unstructured":"Pandhi N, Kajal NC, Malhotra B, Kaur L, Singh A, Kaur G, Shukla AK, Dadra R, Neki NS. To Study Clinico-Radiological Profile of Multi-Drug Resistant Tuberculosis Patients.."},{"issue":"8","key":"10.1016\/j.ijtb.2024.04.011_bib15","first-page":"52","article-title":"Sociodemographic and clinical profile of multi drug resistant tuberculosis patients: a study at drug resistant tuberculosis centres of Kolkata","volume":"14","author":"Mukherjee","year":"2015","journal-title":"OSR Journal of Dental and Medical Sciences (IOSR-JDMS)"},{"issue":"6","key":"10.1016\/j.ijtb.2024.04.011_bib16","article-title":"Risk factors for drug-resistant tuberculosis, the association between comorbidity status and drug-resistant patterns: a retrospective study of previously treated pulmonary tuberculosis in Shandong, China, during 2004\u20132019","volume":"11","author":"Ning-ning","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijtb.2024.04.011_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.04.012","article-title":"Corrigendum to \u2018High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients\u2019 [J Hepatol 72 (2020) 1028\u2013 1029]","volume":"77","author":"Seung","year":"2022","journal-title":"J Hepatol"},{"journal-title":"PMDT guidelines","article-title":"Guidelines of programmatic management of drug resistant tuberculosis in India 2021","year":"2021","key":"10.1016\/j.ijtb.2024.04.011_bib18"},{"key":"10.1016\/j.ijtb.2024.04.011_bib19","article-title":"Fluorescein Diacetate Vital staining for detecting viability of acid-fast bacilli in sputum of pulmonary tuberculosis patients","author":"Puri","year":"2021","journal-title":"Indian J Tubercul"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570724000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570724000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T19:15:26Z","timestamp":1765134926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570724000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":18,"alternative-id":["S0019570724000726"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2024.04.011","relation":{},"ISSN":["0019-5707"],"issn-type":[{"type":"print","value":"0019-5707"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of FDA vital staining in follow UP of DR PTB patients on longer treatment regimen under NTEP","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2024.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}